Search Tag: ASCVD
2021 22 Jun
Lipid-lowering therapy is an effective strategy to reduce cardiovascular mobility and mortality. There is sufficient clinical evidence to demonstrate the clinical benefits of low-density lipoprotein cholesterol (LDL-C) reduction. LDL-C reductions have been seen with the use of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors...Read more
2019 12 Oct
There are five major guidelines on statin use for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). These include the National Institute for Health and Care Excellence (NICE-2014), US Preventive Services Task Force (USPSTF-2016), Canadian Cardiovascular Society (CCS-2016), European Society of Cardiology/European Atherosclerosis...Read more
2019 25 Jul
The benefits of low-dosages of aspirin (75-100mg daily) for the secondary prevention of cardiovascular diseases (CVDs) exceed the risk of bleeding. However, most are still unclear whether aspirin has the same effects on primary prevention. The recent results from three trials ASPREE, ASCEND and ARRIVE each tested the effects of 100mg of aspirin...Read more
2017 01 Aug
Control of a range of cardiovascular risk factors as a result of healthy lifestyle choices, medications and Mendelian randomisation (good genetics) can result in significant reduction of atherosclerotic cardiovascular disease (ASCVD) risk, according to a commentary published in the Canadian Journal of Cardiology. The article cites a study by Bérard...Read more